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REVIEW
Abstract: Circulating lipoprotein-associated phospholipase A2 (Lp-PLA2) is a marker of
inflammation that plays a critical role in atherogenesis; its inhibition may have antiatherogenic
effects. Studies from the West of Scotland Coronary Prevention Study (WOSCOPS),
Monitoring Trends and Determinants in Cardiovascular Diseases (MONICA) and Rotterdam
cohorts have shown that Lp-PLA2 is an independent predictor of coronary heart disease (CHD),
and the association is not attenuated upon multivariate analysis with traditional risk factors
and other inflammatory markers. Studies in subjects with coronary artery disease (CAD)
have also shown associations between Lp-PLA2 and cardiovascular risk. At least two recent
studies have shown that Lp-PLA2 is a risk predictor for stroke. Overall, epidemiological studies
suggest that measurement of Lp-PLA2 in plasma may be a useful in identifying individuals at
high risk for cardiovascular events.
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Introduction
Circulating markers of inflammation may predict cardiovascular risk. Lipoprotein-
associated phospholipase A2 (Lp-PLA2) is a macrophage-derived enzyme from the
phospholipase A2 superfamily that has been shown to be an independent predictor of
cardiovascular disease (CVD) and future events. Several epidemiological and clinical
studies have examined the role of Lp-PLA2 in CVD, and in the aggregate, the evidence
suggests a role for the use of this biomarker in risk prediction.
The role of Lp-PLA2 in atherosclerosis
Lipoprotein-associated phospholipase A2, also known as platelet activating factor
acetylhydrolase (PAF-AH), is a 50 kD Ca
2+-independent phospholipase, distinct from
another macrophage product, secretory PLA2, a 14kD Ca2+-dependent enzyme (Dada
et al 2002). Lp-PLA2 is expressed in atherosclerotic plaques (Hakkinen et al 1999),
and in macrophages within the fibrous cap of human rupture prone lesions (Kolodgie
et al 2004). Lp-PLA2 is transported in plasma predominantly associated with low
density lipoprotein (LDL) (Caslake et al 2000). Lp-PLA2 causes hydrolysis of
modified phospholipids within oxidized LDL (OxLDL), generated by LDL oxidation
in the milieu of the artery wall (MacPhee et al 1999; Ross 1999; MacPhee 2001),
resulting in the production of lysophosphatidylcholine (LysoPC) and oxidized fatty
acids (OxFA) (MacPhee et al 1999). The proinflammatory and atherogenic properties
of LysoPC are well known (Quinn et al 1988; MacPhee et al 1999).
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Lp-PLA2 modulation by pharmacological
interventions
Preclinical studies have shown that inhibition of Lp-PLA2
significantly reduces atherogenesis (MacPhee 2001). Initial
clinical studies suggest that the inhibitors of Lp-PLA2 can
block enzyme activity in plasma and within atherosclerotic
plaques (MacPhee et al 2005). Statins and fibrates are known
to decrease cardiovascular events and reduce plasma Lp-
PLA2 levels (Tsimihodimos et al 2003; Schaefer et al 2005).
There appears to be differences among the statins, with
atorvastatin being more effective than fluvastatin, lovastatin,
pravastatin, or simvastatin for decreasing not just LDL-
cholesterol, but also high sensitive C-reactive protein (hs-
CRP) (32% reduction with atorvastatin) and Lp-PLA2 (26%
reduction with atorvastatin) (Schaefer et al 2005).
Assessment of Lp-PLA2 Levels
Lp-PLA2 mass is measured by an enzyme immunoassay in
human plasma (the PLAC™ test) (Dada et al 2002). In
addition, Lp-PLA2 activity can also be measured in human
plasma (Tselepis et al 2002).
Cardiovascular risk prediction in
clinical studies
WOSCOPS (The West of Scotland Coronary Prevention
Study) was a primary prevention trial designed to evaluate
the use of pravastatin in hypercholesterolemic men (Packard
et al 2000) (Table 1). A 2-fold greater risk of coronary heart
disease (CHD) was observed for patients in the highest
quintile of Lp-PLA2 levels compared with those in the lowest
quintile. Similar to Lp-PLA2, the risk of CHD was 2-fold
greater in the highest quintile of CRP levels and white-cell
count compared with the lowest quintile. However, on
multivariate analysis, risk associated with CRP levels and
white-cell counts was attenuated, but the association of Lp-
PLA2 with risk of CHD remained significant for all quintiles
(p=0.005), demonstrating the strength of Lp-PLA2 as an
independent marker of CHD. Of note, Lp-PLA2 was the
only marker of inflammation whose levels were not affected
by smoking.
The ARIC study (Atherosclerosis Risk in Communities)
(Ballantyne et al 2004) was a prospective study designed to
evaluate atherosclerosis over a period of 6 years in over
12 000 apparently healthy middle-aged men and women. In
a case-cohort analysis, a hazard ratio (HR) of 1.78 (95%
confidence index [CI], 1.33–2.38) for the highest tertile of
Lp-PLA2 (≥422 µg/L) and HR 2.53 (1.88 to 3.40) for the
highest tertile of CRP (>3.0 mg/L) was reported. In patients
with LDL levels below the median (<130mg/dL), both Lp-
PLA2 and CRP levels were significantly and independently
associated with CHD, even in fully adjusted models. Those
individuals with increased levels of both Lp-PLA2 and CRP
were found to have the greatest risk for a CHD event (HR
2.95 CI, 1.47–5.94]).
In a Southern German study examining subjects from
the MONICA (Monitoring Trends and Determinants in
Cardiovascular Diseases) population, the relationship
between Lp-PLA2 levels and risk of coronary events was
evaluated in 934 healthy men aged 45 to 64 years who were
followed for 14 years (Koenig et al 2004). In the 97 men
who suffered a coronary event, mean baseline levels of Lp-
PLA2 were significantly higher in men who had suffered an
event. A 1 standard deviation (SD) increase in Lp-PLA2 mass
Table 1 Studies and trials demonstrating significant independent association between Lp-PLA2 levels and cardiovascular endpoints,
expressed either as HR (highest compared with lowest tertile, quartile, or quintile) or RR per 1 SD
Author Population Endpoints Risk
HR
Ballantyne ARIC: Healthy subjects Coronary events 2.08 (LDL<130)
Ballantyne ARIC: Healthy subjects Stroke 1.97
Khusiyenova Southern Germans: CAD Presence of CAD 1.84
Oei Rotterdam: Elderly Coronary events/stroke 1.96/1.95
RR per 1 SD
Packard WOSCOPS: Hypercholesterolemia Cardiac events  1.18
Brilakis Mayo Clinic study: CAD Cardiac events  1.27
Iribarren CARDIA: Young adults Coronary calcification  1.25
Koenig MONICA: Healthy men Coronary events   1.21
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CAD, coronary artery disease; CARDIA, Coronary Artery Risk Development in Young Adults; HR,
hazard ratio; LDL, low-density lipoprotein; MONICA, Monitoring Trends and Determinants in Cardiovascular Diseases; RR, risk ratio; SD, standard deviation;
WOSCOPS, West of Scotland Coronary Prevention Study.Vascular Health and Risk Management 2006:2(2) 155
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was associated with a 37% increase in risk of future coronary
events, even after controlling for potentially confounding
factors and CRP. The combination of a high Lp-PLA2
(>290.8 µg/L) and a high CRP (>3 mg/L) was consistently
associated with a statistically significantly increased risk
for future coronary events, suggesting that these biomarkers
may be complementary in identifying high-risk subjects.
The Rotterdam Study was a population-based follow-
up study in 7983 subjects aged 55 years and over. Oei et al
(2005) performed a case-cohort study, including 308 CHD
cases, and a random sample of 1820 subjects. Compared
with the first quartile of Lp-PLA2 activity, multivariate-
adjusted HRs for CHD for the second, third, and fourth
quartiles were 1.39 (95% CI, 0.92 to 2.10), 1.99 (95% CI,
1.32 to 3.00), and 1.97 (95% CI, 1.28 to 3.02), respectively
(p for trend=0.01). The Rotterdam study thus provides
additional evidence for an association between Lp-PLA2
and CHD, independent of other risk factors.
One small study (Blake et al 2001) failed to show an
independent association between Lp-PLA2 levels and risk
of CHD. In univariate analysis, mean levels of Lp-PLA2
were significantly higher at baseline among cases than
controls, but the predictive value of Lp-PLA2 was attenuated
after adjustment for other cardiovascular risk factors. This
study examined a small number of women, many of whom
were on hormonal therapy, which may explain the disparate
observations in this study compared with others showing a
relationship between Lp-PLA2 levels and risk of CHD.
Studies of Lp-PLA2 in patients with
angiographic evidence of coronary
artery disease
In a study of 148 men, 48 with angiographically proven
coronary artery disease (CAD), 46 who had suffered
myocardial infarction at least 1 year prior to the study, and
54 normal aged-matched controls (Caslake et al 2000),
elevated levels of Lp-PLA2 were found in patients with
angiographic CAD compared with the normal patients,
independent of LDL and other risk factors including
smoking and systolic blood pressure. Another study
(Khyseyinova et al 2005) in German patients with
angiographic evidence of CAD and in age- and gender-
matched blood donors confirmed that Lp-PLA2
concentrations were significantly higher in cases than in
controls; further age and gender adjusted odds ratio (OR)
for the presence of CAD was 1.61 (95% CI, 1.07–2.44) when
the top quartile of the Lp-PLA2 distribution was compared
with the bottom quartile. Adjustment for traditional
cardiovascular risk factors and statin intake resulted in an
OR of 2.04 (1.19–3.48). An additional study (Brilakis et al
2005) in 504 patients at the Mayo Clinic undergoing
clinically indicated coronary angiography, demonstrated
higher Lp- PLA2 levels were associated with a greater risk
of events: the HR per SD was 1.28 (95% CI, 1.06–1.54,
p=0.009), and remained significant after adjusting for
clinical and lipid variables and CRP.
Lp-PLA2 in young adults with coronary
artery calcification
The association between Lp-PLA2 (mass and activity), and
coronary artery calcification (CAC) in young adults was
examined in a nested case-control study using data from
the Coronary Artery Risk Development in Young Adults
(CARDIA) study (Iribarren et al 2005). Lp-PLA2 mass and
activity were significantly higher in cases than in controls.
The OR of calcified coronary plaque per 1 SD increment
was 1.40 (1.17 to 1.67) and 1.39 (1.14 to 1.70) for Lp-PLA2
mass and activity, respectively; the relationship was
independent of LDL-cholesterol. After adjusting for multiple
covariates, a statistically significant association remained
for Lp-PLA2 mass (1.28; 95% CI, 1.03–1.60) but not for
activity. Thus, Lp-PLA2 (measured as mass) appears to be
involved in early CAC.
Lp-PLA2 as a risk predictor for stroke
Recently, Oei et al (2005) compared 110 ischemic stroke
cases with a random sample of 1820 subjects in a case-cohort
analysis in the Rotterdam study, and also reported a
significant association between Lp-PLA2 activity and
ischemic stroke. Compared with the first quartile of Lp-
PLA2 activity, multivariate-adjusted HRs for ischemic stroke
were 1.08 (95% CI, 0.55 to 2.11), 1.58 (95% CI, 0.82 to
3.04), and 1.97 (95% CI, 1.03 to 3.79) (p for trend=0.03).
In a further analysis from the ARIC study, the relation
between Lp-PLA2, CRP, traditional risk factor (RFs), and
stroke over 6 years was examined (Ballantyne et al 2005).
Both Lp-PLA2 and CRP were associated with stroke after
adjustment for age, sex, and race with a HR of 2.16 for the
highest versus the lowest tertile of Lp-PLA2 and 2.64 for
CRP. In a model including CRP and Lp-PLA2 with
traditional RFs plus body mass index (BMI), triglycerides,
and antihypertensive medication, the highest tertile of Lp-
PLA2 had an HR of 2.04 (1.23–3.38, p<0.01). IndividualsVascular Health and Risk Management 2006:2(2) 156
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with high levels of both CRP and Lp-PLA2 were at the
highest risk after adjusting for traditional risk factors.
Thus, both Lp-PLA2 and CRP may be complementary
beyond traditional risk factors in identifying individuals at
increased risk for stroke. Inflammation may play a role in
the etiology of stroke, reflected at least in some patients by
elevated levels of inflammatory biomarkers, and
antiinflammatory properties of statins may be crucial to their
beneficial effects on stroke reduction.
Conclusions
Lp-PLA2 plays a critical role in atherogenesis, and may
indeed be a marker of inflammation (Sudhir 2005).
Inhibition of Lp-PLA2 may have antiatherogenic effects.
Studies from the WOSCOPS and MONICA cohorts have
shown that the association of Lp-PLA2 with CHD is not
attenuated upon multivariate analysis with other
inflammatory markers and traditional risk factors. Two
recent studies have shown that Lp-PLA2 is a predictor of
stroke risk. Measurement of Lp-PLA2 in plasma may be
useful in identifying subjects at high risk for future
cardiovascular events.
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